News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

MSNZ welcomes consultation period for Tysabri and Gilenya

Media release (8 August 2014)


MSNZ welcomes beginning of consultation period for Tysabri and Gilenya as proposed new first-line treatments for relapsing remitting forms of Multiple Sclerosis.

The Multiple Sclerosis Society of New Zealand (MSNZ) welcomes PHARMAC’s release of a consultation document today that proposes Natalizumab (Tysabri)and Fingolimod (Gilenya) as potential new first-line treatments for relapsing, remitting forms of MS.

PHARMAC is seeking feedback on a funding proposal involving five treatments for multiple sclerosis (MS), including these two new treatments. It is also seeking feedback on potential changes to the currently funded treatments Avonex, Betaferon and Copaxone.

In February, PTAC (the Pharmaceutical Technical Advisory Committee) recommended to PHARMAC that these new treatments be funded as new first-line treatments.

“It has been a long process to get to this point but PHARMAC’s announcement is a positive step,” says MSNZ spokesman Neil Woodhams. “Relapsing Remitting MS is one of four types of MS, affecting the highest percentage of patients. These new treatments, if accepted by PHARMAC, will be given as soon after diagnosis as possible, to patients fitting within the criteria. This is a great start for all those who will benefit from these treatments.”

Subject to a positive outcome from its consultation process, PHARMAC has suggested that Natalizumab and Fingolimod could be listed on the Hospital Medications List by 1 November 2014 and that changes to the restrictions around access to treatments that are currently funded could also be made by that date.

“This is not the end of the process,” says Mr Woodhams. “The next stage of consultation begins today. We recommend that interested parties read the consultation documents carefully as there are restrictions on the access to these treatments and changes that will be made to the currently-funded treatments.”

Submissions on PHARMAC’s consultation document close on 29 August, 2014.

“MSNZ would like to thank everyone involved in the Patients’ Steering Group, the MS Community, neurologists and supporters who have helped to highlight the importance of funding these new first-line treatments. MSNZ has been overwhelmed with the support and commitment shown to date and we urge supporters to maintain their level of engagement during the next stage of the process and beyond.”


More information about the consultation documents:
For more information visit the PHARMAC website:
www.pharmac.health.nz/news/consultation-2014-08-07-mstreatments/

Details of the proposal, including proposed funding access criteria, and some background information can be found at:
www.pharmac.health.nz/assets/consultation-2014-08-07-mstreatments.pdf

Please note: The fingolimod component of this proposal is dependent on a multi-product provisional agreement with Novartis, for a number of other products including fingolimod, being approved. PHARMAC are consulting on the Novartis multiproduct proposal separately, see PHARMAC’s website at: www.pharmac.health.nz/news/consultation-2014-08-07-multiproduct.
www.pharmac.health.nz/assets/consultation-2014-08-07-multiproduct.pdf

About MSNZ:
For more information about MSNZ please email info@msnz.org.nz or call 0800 MS LINE (67 54 63).

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
Gold For RNZ: Muslim Post-9/11 Series, Kim Hill Win In New York

The Radio New Zealand podcast series Public Enemy has won a gold award for excellence for its presenter, Mohamed Hassan, at the prestigious New York Festival Radio Awards announced in Manhattan today. RNZ National’s Saturday Morning host, Kim Hill, also received a gold award for Best Radio Personality. More>>

Human Rights Commission: Give Nothing To Racism

A campaign urging New Zealanders to give nothing to racism and refuse to spread intolerance has been launched by some of the country’s most well-known people. More>>

Louis Vuitton Series Win: Emirates Team NZ Will Challenge For The America’s Cup

By beating Artemis 5-2 they now take on Oracle Team USA in the America’s Cup match starting next weekend. More>>

ALSO:

Monterey: Rodger Fox Big Band Invited To Celebrated Festival

The Rodger Fox Big Band has received an invitation to perform at the 2017 Monterey 60th Anniversary Jazz Festival in the USA in September of this year. More>>

AntARTica: Scientist’s Painting Discovered In Antarctic Hut

The New Zealand Antarctic Heritage Trust has discovered an almost perfectly preserved 118 year old watercolour painting among penguin-excrement, dust and mould covered papers found in an historic hut at Cape Adare, Antarctica. More>>

Scoop Review Of Books: Set In Stone

Tthere are over a thousand public war memorials scattered around the country, commemorating over 30,000 New Zealanders who have died in wartime, and most of whom are buried overseas. More>>>More>>

ALSO:

 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland